<- Go Home
Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Market Cap
$3.7B
Volume
649.6K
Cash and Equivalents
$81.3M
EBITDA
-$202.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$80.99
52 Week Low
$36.93
Dividend
N/A
Price / Book Value
15.35
Price / Earnings
-15.81
Price / Tangible Book Value
15.78
Enterprise Value
$3.5B
Enterprise Value / EBITDA
-17.22
Operating Income
-$204.1M
Return on Equity
105.54%
Return on Assets
-52.40
Cash and Short Term Investments
$289.9M
Debt
$52.8M
Equity
$232.3M
Revenue
N/A
Unlevered FCF
-$33.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium